Cleave Therapeutics
Biotechnology, 135 Main St Ste 1145, San Francisco, California, 94105, United States, 1-10 Employees
Phone Number: 41********
Who is CLEAVE THERAPEUTICS
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic us...
Read More
-
Headquarters: 135 Main St Ste 1145, San Francisco, California, 94105, United States
-
Date Founded: 2011
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from CLEAVE THERAPEUTICS
Cleave Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Cleave Therapeutics
Answer: Cleave Therapeutics's headquarters are located at 135 Main St Ste 1145, San Francisco, California, 94105, United States
Answer: Cleave Therapeutics's phone number is 41********
Answer: Cleave Therapeutics's official website is https://cleavetherapeutics.com
Answer: Cleave Therapeutics's revenue is $1 Million to $5 Million
Answer: Cleave Therapeutics's SIC: 2836
Answer: Cleave Therapeutics's NAICS: 325414
Answer: Cleave Therapeutics has 1-10 employees
Answer: Cleave Therapeutics is in Biotechnology
Answer: Cleave Therapeutics contact info: Phone number: 41******** Website: https://cleavetherapeutics.com
Answer: Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. There is a growing body of evidence around inhibiting VCP to target cancer stress pathways with known biological relevance in cancer. Cleave has ongoing collaborations with the National Cancer Institute (NCI) and leading academic institutions. The company is leveraging this combined expertise to advance VCP/p97 inhibitors for cancer and neurodegenerative disease. VCP is a critical enzyme in the AAA (ATPases Associated with diverse cellular Activities) family of ATPases and is a key regulator of various aspects of protein homeostasis and cellular stress that are critical for cancer cell growth and survival. In neurodegenerative diseases, VCP/p97 has been shown to be important for the health and function of mitochondria, and Cleaves research has demonstrated the potential for therapeutic benefit for patients with limited treatment options with those devastating diseases. Cleaves oncology drug discovery pipeline exploits molecular features that are dependent on VCP/p97 and are key to the growth and survival of cancers cells. Cleaves lead drug development candidate, CB-5339, is a potent, oral, selective, second-generation inhibitor of VCP/p97, which addresses the limitations of earlier compounds, including exposure and selectivity to the target. The company is launching a Phase 1 clinical study in acute myeloid leukemia (AML), for which there is compelling preclinical data and a significant unmet medical need. The National Cancer Institute has a decades long interest in VCP/p97 as a target and is planning to sponsor a Phase I trial with CB-5339 in solid tumors.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month